Albert Lowe
Stock Analyst at Craig-Hallum
(2.95)
# 1,396
Out of 5,150 analysts
10
Total ratings
30%
Success rate
25.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $131.51 | +33.07% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $21.99 | +127.38% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $20 | $4.72 | +323.73% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $4.25 | +41.18% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.74 | +1,802.43% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.89 | +182.78% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $1.89 | +323.28% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.89 | +111.64% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.62 | +270.37% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $131.51
Upside: +33.07%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $21.99
Upside: +127.38%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $20
Current: $4.72
Upside: +323.73%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $4.25
Upside: +41.18%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.74
Upside: +1,802.43%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.89
Upside: +182.78%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $1.89
Upside: +323.28%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.89
Upside: +111.64%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.62
Upside: +270.37%